Iteos Therapeutics Inc

Iteos Therapeutics — Corporate Update (April 2021)

19 slides from Iteos Therapeutics's corporate update, Apr 12, 2021

  1. Slide 1: EOS-448 update - April 12th, 2021

    Immunotherapies to Improve and Extend the Lives of People with Cancer EOS-448 update - April 12th, 2021 Exhibit 99.2

  2. Slide 2: Disclaimer

    Disclaimer This Presentation has been prepared by iTeos Therapeutics, Inc. (“we,” “us,” our “our”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are neither historical f

  3. Slide 3: iTeos Made Great Progress in 2020

    iTeos Made Great Progress in 2020 Building the Foundation to Support the Evolution of our Pipeline Integrated pioneering work in tumor immunology from Ludwig Cancer Research to build our immuno-oncology drug discovery and development capabilities Continued to develop EOS-448, a FcgR-engaging anti-TI

  4. Slide 4: FcgR-engaging Anti-TIGIT Antibody Program Update EOS-448

    Fc��R-engaging Anti-TIGIT Antibody Program Update EOS-448 EOS-448

  5. Slide 5: EOS-448: FcgR-Engaging Anti-TIGIT Antibody

    EOS-448: Fc��R-Engaging Anti-TIGIT Antibody EOS-448 EOS-448 is an anti-TIGIT antibody targeted therapy designed to achieve maximal immune stimulatory effects High TIGIT binding affinity and selected to maximize potency IgG1 isotype antibody, containing an Fc domain with the ability to engage Fc��R-e

  6. Slide 6: EOS-448 Is Designed to Enhance the Anti-tumor Response Through Multifaceted Immune Modulation

    EOS-448 Is Designed to Enhance the Anti-tumor Response Through a Multifaceted Immune Modulation Mechanism Tumor cell CD155 CD226 CD112 TIGIThigh Treg and exhausted T cells FCgR FCgR NK Macro phages DC TIGIT NK or T cell TIGIT EOS-448 EOS-448 Pro-inflammatory cytokines T cell and NK cell killing of t

  7. Slide 7: AACR 2021 Phase 1 first-in-human study in patients with advanced cancers

    AACR 2021 Phase 1 first-in-human study in patients with advanced cancers EOS-448 EOS-448

  8. Slide 8: First-in-human Phase 1 Trial of EOS-448 in Patients with Advanced Solid Tumors

    First-in-human Phase 1 Trial of EOS-448 in Patients with Advanced Solid Tumors First-in-human, open-label dose-escalation, phase 1 trial (NCT04335253) in adults with advanced solid tumors for whom no standard treatment was available. Baseline characteristics Advanced or metastatic cancer for whom no

  9. Slide 9: Early Clinical Activity as Monotherapy in Patients with Advanced Cancers

    Early Clinical Activity as Monotherapy in Patients with Advanced Cancers Who Have Exhausted Treatment Options Response Evaluable Patients [n] (N=20) Best Overall Response [n (%)] Complete Response (CR) 0 (0%) Partial Response (PR) 1 (5%) Stable Disease (SD) 9 (45%) Progressive Disease (PD) 10 (50%)

  10. Slide 10: Early Clinical Activity as Monotherapy: Best Change from Baseline and Response Duration

    Early Clinical Activity as Monotherapy in Patients with Advanced Cancers Who Have Exhausted Treatment Options Best Change from Baseline and Response Duration in Target Lesions on Investigator Assessment per Recist v1.1 Swimmer plot of Study Treatment Period, Best Response and Progression Sacral Van

  11. Slide 11: Confirmed Partial Response in a Patient with Pembrolizumab-resistant Melanoma

    Confirmed Partial Response in a Patient with Pembrolizumab-resistant Melanoma Partial response in a 65-year-old female with BRAF mutant Cutaneous Melanoma 2 prior lines of therapy: BRAF-MEK inhibitor combo followed by pembrolizumab with documented PD Confirmed PR per RECIST with a 58% reduction in s

  12. Slide 12: Manageable Tolerability Profile, Consistent with Other Checkpoint Inhibitors

    Manageable Tolerability Profile, Consistent with Other Checkpoint Inhibitors Adverse Event Summary in Patients Treated with EOS-448 TEAE Related to EOS-448 Occurring in at Least 2 Patients by Preferred Term, Number (%) of Patients (N=22) Patients with At Least One [n (%)] TEAE Related to EOS-448 18

  13. Slide 13: Strong depletion of TIGIT+ suppressive Tregs observed at all doses

    Strong depletion of TIGIT+ suppressive Tregs observed at all doses Evidence for Fc��R-Engagement and Depletion of TIGIT+ Suppressive Tregs Van den Mooter, TFA et al. AACR 2021.

  14. Slide 14: Depletion of TIGIT+ suppressive Tregs observed throughout dosing interval

    Depletion TIGIT+ suppressive Tregs observed throughout dosing interval Evidence for Fc��R-Engagement and Depletion of TIGIT+ Suppressive Tregs and Exhausted T cells Van den Mooter, TFA et al. AACR 2021. CD8+ T cells (200mg Q2W) Tregs (200mg Q2W) Depletion TIGIT+ CD8+ exhausted T cells and restoratio

  15. Slide 15: FcgR-engaging Anti-TIGIT Antibody: Advancement in next stage of clinical development

    Fc��R-engaging Anti-TIGIT Antibody Advancement in next stage of clinical development EOS-448 EOS-448

  16. Slide 16: Currently Anticipated EOS-448 Phase 1/2a Clinical Plan

    Currently Anticipated EOS-448 Phase 1/2a Clinical Plan: Novel Combinations in Settings with Significant Clinical Need Trials in three checkpoint-naïve and resistant settings Phase 1b Safety and PK/PD Phase 2a Disease-specific trials Anticipate start in mid-2021 EOS-448 + IMID Multiple Myeloma EOS-44

  17. Slide 17: EOS-448: Encouraging Results and Rapid Advancement into Next Stage of Clinical Development

    EOS-448: Encouraging Results and Rapid Advancement into Next Stage of Clinical Development EOS-448 showed a favorable tolerability profile and early signs of clinical activity in advanced cancer patients who have exhausted treatment options Promising early clinical activity as monotherapy, including

  18. Slide 18: iTeos has Built the Foundation to Support Transformative Acceleration in 2021

    iTeos has Built the Foundation to Support Transformative Acceleration in 2021 Exciting partial responses in difficult-to-treat patients Progress EOS-448 and Inupadenant in multiple tumor types with different combinations Anticipate additional updates on programs in the near future Company well capit

  19. Slide 19: *JiTeos

    *JiTeos

iTeos Therapeutics — Corporate Update (April 2021) on 6ix